SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf [Yahoo! Finance]
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: Yahoo! Finance
preserving regulatory T cells to preserve pancreatic beta cells, and SAB says it is redosable and avoids the serum sickness, anti-drug antibodies and ADCC-driven lymphodepletion seen with rabbit ATG. The global Phase IIb SAFEGUARD trial targets newly diagnosed Stage 3 T1D patients (ages 5–40) with 2.5 mg/kg, 1.5 mg/kg and placebo arms dosed every six months, uses 1-year C-peptide as the primary endpoint, is considered by the company and FDA to be pivotal, and plans last patient in by end-2026 with top-line data in H2 2027. SAB ended 2025 with $140 million in cash, which management says funds SAFEGUARD through top-line readout plus about one additional year into 2028, while citing an initial U.S. addressable market of ~64,000 new Stage 3 diagnoses per year and using Tzield's ~$200,000 price as a commercial reference. Interested in SAB Biotherapeutics, Inc.? Here are five stocks we like better. Promising Upsides on these Biotech Penny Stocks SAB Biotherapeutics (NASDAQ:SABS) u
Show less
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SAB BIO to Participate in Upcoming Investor ConferencesGlobeNewswire
- SAB BIO to Participate in Upcoming Investor ConferencesGlobeNewswire
- SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- SAB BIO Strengthens Board of Directors with Appointment of New Chair and New DirectorGlobeNewswire
- SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.MarketBeat
SABS
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- 2/5/26 - Form 4
- SABS's page on the SEC website